Citations

Showing 10 of 108152 citations.

Effects of p56 lck Deficiency on the Growth and Cytolytic Effector Function of an Interleukin-2-Dependent Cytotoxic T-Cell Line
Karnitz, Larry M., Sutor, Shari L., Reed, John C. , Bell, Michael P., McKean, D J, Leibson, Paul J., Abraham, Robert T. , Torigoe, Toshihiko

Mayo Clinic

Molecular and Cellular Biology | June 7, 2021 | Volume: 12 | Issue: 10 | Pages: 4521-4530

10.1128/mcb.12.10.4521-4530.1992 | PMID 1406641 Get It

Plant Proteins and Exercise: What Role Can Plant Proteins Have in Promoting Adaptations to Exercise?
Kerksick, Chad M. , Jagim, Andrew R. , Hagele, Anthony M. , Jäger, Ralf , Jagim, Andrew R , Kerksick, Chad M

Mayo Clinic

Nutrients | June 7, 2021 | Volume: 13 | Issue: 6 | Pages: 1962

10.3390/nu13061962 | PMID 34200501 Get It

Adequate dietary protein is important for many aspects of health with current evidence suggesting that exercising individuals need greater amounts of protein. When assessing protein quality, animal sources of protein routinely rank amongst the highest in quality, largely due to the higher levels of essential amino acids they possess in addition to exhibiting more favorable levels of digestibility and absorption patterns of the amino acids. In recent years, the inclusion of plant protein sources in the diet has grown and evidence continues to accumulate on the comparison of various plant protein sources and animal protein sources in their ability to stimulate muscle protein synthesis (MPS), heighten exercise training adaptations, and facilitate recovery from exercise. Without question, the most robust changes in MPS come from efficacious doses of a whey protein isolate, but several studies have highlighted the successful ability of different plant sources to significantly elevate resting rates of MPS. In terms of facilitating prolonged adaptations to exercise training, multiple studies have indicated that a dose of plant protein that offers enough essential amino acids, especially leucine, consumed over 8–12 weeks can stimulate similar adaptations as seen with animal protein sources. More research is needed to see if longer supplementation periods maintain equivalence between the protein sources. Several practices exist whereby the anabolic potential of a plant protein source can be improved and generally, more research is needed to best understand which practice (if any) offers notable advantages. In conclusion, as one considers the favorable health implications of increasing plant intake as well as environmental sustainability, the interest in consuming more plant proteins will continue to be present. The evidence base for plant proteins in exercising individuals has seen impressive growth with many of these findings now indicating that consumption of a plant protein source in an efficacious dose (typically larger than an animal protein) can instigate similar and favorable changes in amino acid update, MPS rates, and exercise training adaptations such as strength and body composition as well as recovery.
Fast 3D MR elastography of the whole brain using spiral staircase: Data acquisition, image reconstruction, and joint deblurring
Peng, Xi , Sui, Yi , Trzasko, Joshua D. , Glaser, Kevin J. , Pipe, James G. , Peng, Xi , Sui, Yi , Huston, John , Ehman, Richard L.

Mayo Clinic

Magnetic Resonance in Medicine | June 7, 2021 | Volume: 86 | Issue: 4 | Pages: 2011-2024

10.1002/mrm.28855 | PMID 34096097 Get It

PurposeTo address the need for a method to acquire 3D data for MR elastography (MRE) of the whole brain with substantially improved spatial resolution, high SNR, and reduced acquisition time compared with conventional methods.MethodsWe combined a novel 3D spiral staircase data‐acquisition method with a spoiled gradient‐echo pulse sequence and MRE motion‐encoding gradients (MEGs). The spiral‐out acquisition permitted use of longer‐duration motion‐encoding gradients (ie, over two full oscillatory cycles) to enhance displacement SNR, while still maintaining a reasonably short TE for good phase‐SNR. Through‐plane parallel imaging with low noise penalties was implemented to accelerate acquisition along the slice direction. Shared anatomical information was exploited in the deblurring procedure to further boost SNR for stiffness inversion.ResultsIn vivo and phantom experiments demonstrated the feasibility of the proposed method in producing brain MRE results comparable to the spin‐echo–based approaches, both qualitatively and quantitatively. High‐resolution (2‐mm isotropic) brain MRE data were acquired in 5 minutes using our method with good SNR. Joint deblurring with shared anatomical information produced SNR‐enhanced images, leading to upward stiffness estimation.ConclusionA novel 3D gradient‐echo–based approach has been designed and implemented, and shown to have promising potential for fast and high‐resolution in vivo MRE of the whole brain.
Epinephrine Does Not Influence Baroreflex Sensitivity During Lower Body Negative Pressure to Physiological Tolerance
Scruggs, Zachariah M., Petersen‐Jones, Humphrey G., Convertino, Víctor A. , Joyner, Michael J. , Curry, Timothy B. , Baker, Sarah E.

Mayo Clinic

The FASEB Journal | June 7, 2021 | Volume: 31 | Issue: S1 | Pages: No page available

10.1096/fasebj.31.1_supplement.1087.3 Get It

Background The baroreflex plays an integral role in blood pressure maintenance by altering heart rate and sympathetic activity in response to changes in arterial pressure. Baroreflex sensitivity (BRS) has been shown to decrease linearly during progressive exposure to central hypovolemia as induced by lower body negative pressure (LBNP), and can be used as an index of decompensation status during hemorrhage. Circulating epinephrine is significantly elevated during high stress situations such as hemorrhage; however, it is unclear whether epinephrine influences BRS during progressive exposure to central hypovolemia. Based on previous work, we hypothesized epinephrine would attenuate any reduction in spontaneous cardiac baroreflex sensitivity during LBNP. Methods Ten young (35±3 yrs), healthy (BMI 24±1 kg/m 2 ) men and women (6M/4F) underwent LBNP protocols on 2 separate days consisting of a 10‐min pre‐infusion baseline, 15‐min infusion period (randomized to saline or epinephrine, 0.1 μg/kg/min), 10‐min post‐infusion baseline, and 5 minutes of LBNP at −15, −30, −45, −60, −70, and −80 mmHg until the onset of presyncope (range= −30 to −80 mmHg). Presyncope was defined as a rapid decrease in systolic blood pressure greater than 15 mmHg, systolic blood pressure less than 80 mmHg, bradycardia, or voluntary termination due to presyncopal symptoms. Heart rate (HR; electrocardiogram) and blood pressure (BP; radial arterial catheter) were recorded continuously. Spontaneous cardiac BRS was determined using the sequence method (WinCPRS). Data are reported from both 10‐min baselines and from 1 minute at 20, 40, 60, 80, and 100 percent of each individual's total LBNP exposure time. Results We observed no significant differences in total exposure time (1475±150 vs. 1415±79s; p=0.69) or cumulative stress index (820±135 vs. 699±69 min*mmHg; p=0.37) between saline and epinephrine visits, respectively. Baroreflex sensitivity did not change during post‐infusion baselines (ΔDown‐Down =−2±1 vs. −2±2 ms/mmHg; saline vs. epinephrine, respectively; p=0.09). Baroreflex sensitivity was significantly reduced with LBNP (p<0.01 main effect of LBNP). There was no difference between the change in baroreflex sensitivity during LBNP with saline or epinephrine infusion (ΔDown‐Down =−14±4 vs. −8±4 ms/mmHg, p=0.17). Conclusions Consistent with previous work, spontaneous cardiac baroreflex sensitivity fell during LBNP. Contrary to our hypothesis, epinephrine infusion did not attenuate the fall in spontaneous cardiac baroreflex sensitivity observed during simulated blood loss. Because epinephrine did not alter the effect of LBNP on BRS, these data suggest that BRS may accurately reflect decompensation status during traumatic hemorrhage independent of elevated circulating epinephrine. Support or Funding Information US Army Medical Research and Materiel Command Contract W81XWH‐13‐2‐0038
Extracorporeal Shockwave Therapy in the Management of Sports Medicine Injuries
Schroeder, Allison N. , Tenforde, Adam S. , Jelsing, Elena J.

Mayo Clinic

Current Sports Medicine Reports | June 7, 2021 | Volume: 20 | Issue: 6 | Pages: 298-305

10.1249/jsr.0000000000000851 | PMID 34099607 Get It

Abstract Treatment of musculoskeletal conditions in athletes with extracorporeal shockwave therapy (ESWT) is gaining popularity as greater evidence supports its use. ESWT protocols (describing energy flux density, number of impulses, type of shockwave (focused or radial), number/frequency/duration of treatment session, area of application, and postprocedural therapy protocols) can be adjusted in the clinical setting. Protocols vary across studies, and optimal protocols for most indications are yet to be determined. ESWT can safely be used to treat various musculoskeletal conditions in athletes, including rotator cuff tendinopathy, lateral elbow epicondlyopathy, greater trochanteric pain syndrome, hamstring tendinopathy, patellar tendinopathy, Achilles tendinopathy, other tendinopathies, plantar fasciopathy, bone stress injuries, and medial tibial stress syndrome. ESWT can be used to treat in-season athletes, as it often requires no/minimal time away from sport and may result in rapid benefits. ESWT should be used in conjunction with physical therapy to facilitate longer-term gains in function and to optimize healing.
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines
Eckel‐Passow, Jeanette E. , Kitange, Gaspar J. , Decker, Paul A. , Kosel, Matthew , Oberg, Ann L. , Sarkaria, Jann N. , Burgenske, Danielle M. , Sarkaria, Jann N , Decker, Paul A.

Mayo Clinic

Neuro-Oncology | June 7, 2021 | Volume: 23 | Issue: 12 | Pages: 2066-2075

10.1093/neuonc/noab137 | PMID 34107029 Get It

Abstract Background Appropriately designed preclinical patient-derived xenograft (PDX) experiments are important to accurately inform human clinical trials. There is little experimental design guidance regarding choosing the number of PDX lines to study, and the number of mice within each PDX line. Methods Retrospective data from IDH-wildtype glioblastoma preclinical experiments evaluating a uniform regimen of fractionated radiation (RT), temozolomide (TMZ) chemotherapy, and concurrent RT/TMZ across 27 PDX lines were used to evaluate experimental designs and empirically estimate statistical power for ANOVA and Cox regression. Results Increasing the number of PDX lines resulted in more precise and reproducible estimates of effect size. To achieve 80% statistical power using ANOVA, experiments using a single PDX line required subsampling of 6 mice per PDX for each treatment group to detect a difference in survival of 135 days, and 9 mice per PDX to detect a difference of 100 days. Alternatively, a design that used 10 PDX lines had greater than 80% power to detect a difference of 135 days with a single mouse per PDX per treatment group, a difference of 100 days with 2 mice per PDX per treatment, and 35 days with more than 10 mice per PDX per treatment. Power for Cox regression was slightly smaller than ANOVA for very small experiments regardless of effect size and slightly higher than ANOVA for detecting a smaller effect size of 35 days difference in survival for moderate-to-large experiments. Conclusions Experimental designs using few mice across many PDX lines can provide robust results and account for inter-tumor variability.
Mobile Health Application for Patients Undergoing Breast Cancer Surgery: Feasibility Study
Ponder, Madison , Venkatraman, Vishal , Charalambous, Lefko T. , Ansah-Yeboah, Abena A. , Adil, Syed M. , Antezana, Luis A. , Dharmapurikar, Rajeev , Gellad, Ziad F. , Lad, Shivanand P. , Hwang, E. Shelley , Plichta, Jennifer K. , Hwang, E. Shelley , Charalambous, Lefko , Antezana, Luis , Plichta, Jennifer K

Mayo Clinic

JCO Oncology Practice | June 7, 2021 | Volume: 17 | Issue: 9 | Pages: e1344-e1353

10.1200/op.20.01026 | PMID 34097502 Get It

PURPOSE: Contemporary breast cancer surgery often requires hospital stays of 1 day or less, presenting challenges to delivery of high-quality care. Without sufficient time for proper education and guidance, patients may delay seeking care, experience anxiety, or seek unnecessary care, leading to poorer outcomes and increased costs. To address this, we evaluated the feasibility of a planning-, outcomes-, and analytics-based mobile health application called Manage My Surgery (MMS) for patients undergoing elective breast cancer surgery. METHODS: Patients undergoing breast cancer surgery at an academic health center were invited to use MMS. Those who used the application received pre- and postoperative surveys, which recorded and reported patient satisfaction and outcomes related to the application. RESULTS: Thirty-three female patients undergoing elective breast cancer surgery used MMS. The median age was 58 years. Nineteen patients underwent lumpectomy, and 14 underwent mastectomy. Users logged on to the application an average of 3.5 times. The median number of questions viewed was 12 (range 2-35). Of 17 patients who completed the feedback survey, 100% said that MMS was helpful during preparation for surgery, 82.3% said that MMS was helpful postoperatively, and 94.1% would recommend MMS to others. Preliminary data on patient-reported outcomes collected by MMS suggest improvements in anxiety and depression over time. CONCLUSION: Implementation of a digital care navigation tool in breast cancer surgery patients is feasible. Patients found the tool helpful in both the pre- and postoperative period. Additional ongoing work will focus on patients' self-management skills, long-term outcomes, and health system costs.
The Many Faces of Purpura: Vancomycin-Induced Leukocytoclastic Vasculitis
Zadroga, John A., Mogulla, Vanajakshi , Grant, Christopher, Jevtic, Dorde , Virata, Andrew, Dumic, Igor , Jevtic, Djordje , Dumic, Igor

Mayo Clinic

Case Reports in Infectious Diseases | June 7, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-4

10.1155/2021/9932425 | PMID 34194855 Get It

Leukocytoclastic vasculitis is a rare form of immune-mediated vasculitis that might be caused by infections or autoimmune diseases or might be precipitated by specific medications. We describe a 65-year-old patient, who was receiving vancomycin for a methicillin-sensitive Staphylococcus aureus permacath infection. Vancomycin was chosen due to medication non-adherence and the patient’s desire to receive antimicrobial therapy in conjunction with his scheduled dialysis sessions. The patient’s medical history was notable for untreated hepatitis C infection and end-stage renal disease, requiring hemodialysis three times a week. Vancomycin was administered during dialysis sessions. After one week of therapy, the patient developed bilateral lower extremity purpura. Skin biopsy was suggestive of leukocytoclastic vasculitis with an absence of intravascular thrombi. Serum cryoglobulins were negative, making cryoglobulinemia due to HCV infection unlikely. Following cessation of vancomycin therapy, the rash gradually disappeared with scarring in the form of post-purpuric hyperpigmentation. Despite its widespread use, vancomycin is a rare cause of leukocytoclastic vasculitis. Clinicians should keep in mind a wide range of differential diagnosis of bilateral lower extremity purpura as treatment differs depending on its underlying etiology.
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis
González, Yuri Sánchez , Clark, Ryan , Xie, Wangang, Louis, Édouard , Loftus, Edward V. , Panés, Julián , Panes, Julian , Loftus, Edward V , Ghosh, Subrata , Zhou, Wen , Louis, Edouard , Danese, Silvio

Mayo Clinic

Journal of Crohn's and Colitis | June 7, 2021 | Volume: 15 | Issue: 12 | Pages: 2022-2030

10.1093/ecco-jcc/jjab099 | PMID 34107013 Get It

Abstract Background and Aims Bowel urgency and abdominal pain are impactful, yet under-appreciated ulcerative colitis symptoms and not commonly assessed in clinical trials. We evaluated how these symptoms may improve with upadacitinib treatment and correlate with clinical and health-related quality of life [HRQOL] outcomes in the phase 2b U-ACHIEVE study. Methods Patients aged 18–75 years, with moderately to severely active ulcerative colitis, were randomised to receive placebo or upadacitinib (7.5, 15, 30, or 45 mg once daily [QD]). Bowel urgency and abdominal pain were evaluated at baseline and Weeks 2, 4, 6, and 8. Week 8 correlations were evaluated between bowel urgency/abdominal pain with clinical [Mayo subscores and high-sensitivity C-reactive protein and faecal calprotectin measurements] and HRQOL outcomes [Inflammatory Bowel Disease Questionnaire and 36-Item Short Form Health Survey scores]. Results A greater proportion of patients [n = 250] reported no bowel urgency and less abdominal pain with upadacitinib treatment compared with placebo, with improvements observed as early as 2 weeks. At Week 8, patients receiving the 45-mg QD dose had the greatest improvements versus placebo, with 46% reporting no bowel urgency [vs 9%; p ≤ 0.001] and 38% reporting no abdominal pain [vs 13%; p = 0.015]. At Week 8, moderate correlations were found between bowel urgency or abdominal pain and most clinical and HRQOL outcomes. Conclusions Induction treatment with upadacitinib demonstrated significant reductions in bowel urgency and abdominal pain compared with placebo. These symptoms also correlate to clinical and HRQOL outcomes, supporting their use to monitor disease severity and other treatment outcomes.